Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBT (2016 - 2025)

Perspective Therapeutics' EBT history spans 16 years, with the latest figure at -$26.0 million for Q3 2025.

  • For Q3 2025, EBT fell 71.73% year-over-year to -$26.0 million; the TTM value through Sep 2025 reached -$108.0 million, down 1752.66%, while the annual FY2024 figure was -$80.0 million, N/A changed from the prior year.
  • EBT for Q3 2025 was -$26.0 million at Perspective Therapeutics, down from -$22.0 million in the prior quarter.
  • Across five years, EBT topped out at $32.3 million in Q4 2023 and bottomed at -$41.8 million in Q4 2024.
  • The 5-year median for EBT is -$9.4 million (2023), against an average of -$8.3 million.
  • The largest annual shift saw EBT tumbled 681.82% in 2022 before it skyrocketed 1784.01% in 2023.
  • A 5-year view of EBT shows it stood at $330000.0 in 2021, then crashed by 681.82% to -$1.9 million in 2022, then surged by 1784.01% to $32.3 million in 2023, then tumbled by 229.37% to -$41.8 million in 2024, then skyrocketed by 37.91% to -$26.0 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's EBT are -$26.0 million (Q3 2025), -$22.0 million (Q2 2025), and -$18.2 million (Q1 2025).